DGK Wissenschaftspreis Lipidstoffwechsel (Abstractpreis)
Diskussionsleiter: W. Koenig (München), U. Laufs (Leipzig), N. Marx (Aachen), A. M. Zeiher (Frankfurt am Main)
| (P1098) | Atheroprotective effects of gut microbiota related metabolite propionate by immune-dependent regulation of intestinal cholesterol metabolism | |
| F. L. Zimmermann, P. Schumann, A. Jasina, J. Rößler, D. Schmidt, V. Nageswaran, U. Ceglarek, R. Cineus, A. Hegazy, E. Van der Vorst, Y. Döring, I. Nemet, V. Tremaroli, N. Kränkel, D. Leistner, M. Heimesaat, S. Bereswill, O. Söhnlein, D. N. Müller, F. Bäckhed, S. L. Hazen, A. Haghikia, U. Landmesser, A. Haghikia (Berlin, Leipzig, München, Bochum; Cleveland, US; Göteborg, SE) | ||
| (P1099) | Target populations and treatment cost for Bempedoic acid and PCSK9 inhibitors: a simulation study in the contemporary CAD cohort INTERCATH | |
| C. Blaum, C. Waldeyer, A. Goßling, F. Kröger, B. Bay, T. Lorenz, J. Brätz, A. Graef, T. Zeller, R. Schnabel, P. M. Clemmensen, D. Westermann, S. Blankenberg, M. Seiffert, F. J. Brunner (Hamburg) | ||
| (P1100) | Acute coronary syndrome is associated with a substantial change in the platelet lipidome | |
| T. Harm, A. Goldschmied, K. Dittrich, M. Chatterjee, K. Kolb, T. Castor, T. Geisler, D. Rath, M. Lämmerhofer, M. Gawaz (Tübingen) | ||
| (P1101) | S1P Loading korrigiert eine eingeschränkte HDL vermittelte Kardioprotektion bei Patienten mit koronarer Herzkrankheit | |
| L. K. Dannenberg, A. Polzin, N. Schröder, A. Ayhan, M. Benkhoff, S. Weske, J. Vogt, T. Zeus, T. Müller, M. Gräler, T. Petzold, M. Kelm, B. Levkau (Düsseldorf, Essen, Jena, München) | ||
| (P1102) | Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis | |
| Y. Lin, C. Parco, A. Karathanos, T. Krieger, V. Schulze, N. Chernyak, A. Icks, M. Kelm, M. Brockmeyer, G. Wolff (Düsseldorf) | ||
| (P1103) | CLEC4E is a key player in phagocytosis of cholesterol crystals | |
| P. Pfeifer, M. Steinmetz, S.-T. Habel, J. Lorenz, A. Ackerschott, H.-D. Dregger, J. Jehle, G. Nickenig, S. Zimmer (Bonn) | ||
| (P1104) | Effects of Empagliflozin on Lipoprotein Subfractions in Patients with Type 2 Diabetes | |
| M. Rau, K. Thiele, N.-U. Hartmann, J. Möllmann, S. Wied, M. Böhm, H. Scharnagl, W. März, N. Marx, M. Lehrke (Aachen, Homburg/Saar, Graz, Mannheim) | ||
| (P1105) | Lipid lowering therapy in primary and secondary prevention across Europe: are LDL-C goals achieved in Germany? Results from the DA VINCI study | |
| I. Gouni-Berthold, F. Schaper, U. Schatz, U. Fraass, A. Tabbert-Zitzler, K. Ray (Cologne, Dresden, Munich; London, UK) | ||
| (P1106) | The association of cholesterol metabolism with in-stent stenosis after PCI for stable coronary artery disease | |
| S. Otto, D. Lütjohann, A. Kersiek, S. Friedrichs, C. Schulze, T. Pörner, O. Weingärtner (Jena, Bonn, Aachen) | ||
| (P1107) | Macrophage-specific IRF5 deficiency stabilizes atherosclerotic plaques in ApoE-/- mice | |
| J. Leipner, C. Härdtner, B. Dufner, N. Hoppe, C. Bode, I. Hilgendorf (Freiburg im Breisgau) |